- 3
- 4

Ruairi C. Robertson<sup>a</sup>, James A. Church<sup>a,b</sup>, Thaddeus J. Edens<sup>c</sup>, Kuda Mutasa<sup>b</sup>, Hyun
Min Geum<sup>d</sup>, Iman Baharmand<sup>d</sup>, Sandeep K. Gill<sup>d,e</sup>, Robert Ntozini<sup>b</sup>, Bernard
Chasekwa<sup>b</sup>, Lynnea Carr<sup>d,f</sup>, Florence D. Majo<sup>b</sup>, Beth D. Kirkpatrick<sup>g</sup>, Benjamin Lee<sup>g</sup>,
Lawrence H. Moulton<sup>h</sup>, Jean H. Humphrey<sup>b,h</sup>, Andrew J. Prendergast<sup>a,b,h\*</sup>, Amee R.
Manges<sup>d,e,\*</sup> and the SHINE Trial Team<sup>i</sup>

- 10
- 11
- <sup>a</sup>Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, London,
  UK
- 14 <sup>b</sup>Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
- 15 °Devil's Staircase Consulting, West Vancouver, British Columbia, Canada
- 16 <sup>d</sup>British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
- 17 eSchool of Population and Public Health, University of British Columbia, Vancouver, Canada
- 18 <sup>f</sup>Department of Microbiology and Immunology, University of British Columbia, Canada
- 19 <sup>g</sup>Vaccine Testing Center, College of Medicine, University of Vermont, Burlington, Vermont
- <sup>h</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
   USA
- <sup>1</sup>Members of the SHINE Trial team who are not named authors are listed in
   <u>https://academic.oup.com/cid/article/61/suppl\_7/S685/358186</u>
- 24 \*Co-senior authors
- 25
- 26
- Corresponding author: Ruairi C. Robertson, Centre for Genomics & Child Health, Blizard Institute, 4
   Newark Street, London E1 2AT, United Kingdom. E-mail: r.robertson@qmul.ac.uk.
- 29
- 30
- 31
- 32
- 52
- 33
- 34

#### 35 ABSTRACT

36

*Background:* Oral rotavirus vaccine (RVV) immunogenicity is considerably lower in low- versus
high-income populations; however, the mechanisms underlying this remain unclear. Previous
evidence suggests that the gut microbiota may contribute to differences in oral vaccine
efficacy.

41

42 *Methods:* We performed whole metagenome shotgun sequencing on stool samples and 43 measured anti-rotavirus immunoglobulin A in plasma samples from a subset of infants enrolled 44 in a cluster randomized 2×2 factorial trial of improved water, sanitation and hygiene and infant 45 feeding in rural Zimbabwe (SHINE trial: NCT01824940). We examined taxonomic and 46 functional microbiome composition using random forest models, differential abundance testing 47 and regression analyses to explored associations with RVV immunogenicity.

48

49 Results: Among 158 infants with stool samples and anti-rotavirus IgA titres, 34 were RVV 50 seroconverters. The median age at stool collection was 43 days. The infant microbiome was 51 dominated by *Bifidobacterium longum*. The gut microbiome differed significantly between early 52 (≤42 days) and later samples (>42 days) however, we observed no meaningful differences in 53 alpha diversity, beta diversity, species composition or functional metagenomic composition by 54 RVV seroconversion status. Bacteroides thetaiotaomicron was the only species associated 55 with anti-rotavirus IgA titre. Random forest models poorly classified seroconversion status by 56 both composition and functional microbiome variables.

57

58 *Conclusions:* RVV immunogenicity is low in this rural Zimbabwean setting, however it is not 59 explained by the composition or function of the early-life gut microbiome. Further research is 60 warranted to examine the mechanisms of poor oral RVV efficacy in low-income countries. 61

62 Key words: microbiota, microbiome, rotavirus, shotgun metagenomics, oral rotavirus vaccine

#### 63 **INTRODUCTION**

64 Rotavirus is the leading cause of diarrheal morbidity and mortality in children [1]. Although several oral rotavirus vaccines (RVV) are currently available globally, their 65 efficacy varies substantially by population, limiting their impact [2]. Large efficacy 66 studies show RVV efficacy of 85-98% against severe rotavirus gastroenteritis in high-67 68 income settings [3, 4], compared to only 48% and 39% in South Asia [5] and sub-Saharan Africa [6] respectively. The reasons for poor oral vaccine efficacy in low-69 70 income populations remain poorly understood, however intestinal factors may contribute [7-9]. 71

The gut microbiota plays a critical role in the maturation of early-life immune 72 function and intestinal development [10]. The composition of the early-life gut 73 microbiota may also influence susceptibility to viral infections, since antibiotic 74 treatment and segmented filamentous bacteria both reduce the pathogenicity of 75 76 rotavirus in mice [11, 12]. Emerging evidence suggests that the early-life gut microbiota influences oral vaccine responses by modulating the immune and 77 metabolic environments of the intestine [13]. In mice, antibiotic treatment impairs 78 vaccine responses, an effect that is reversed following restoration of the microbiota 79 [14]. In adults, narrow-spectrum antibiotics did not alter absolute anti-RV IgA titres 80 81 following RVV, but did lead to a higher proportion of individuals displaying short-term IqA "boosting" (defined as a ≥2-fold rise in anti-RV titre 7 days post-vaccination) 82 compared with placebo or broad-spectrum antibiotics [15]. Observational evidence 83 from children in low-income settings has shown no consistent association between the 84 gut microbiota and RVV efficacy in India [16], while RVV immunogenicity was 85 associated with gut microbiota composition in cohorts in Pakistan [17] and Ghana [18]. 86

In these settings, RVV seroconverters compared to non-seroconverters displayed a
gut microbiota more similar to infants from a high-income setting.

We recently reported outcomes of a cluster-randomized trial of improved water, 89 sanitation and hygiene (WASH) in rural Zimbabwe [19]. Among a subset of infants in 90 whom anti-rotavirus IgA titres were measured, only 24% infants seroconverted 91 92 following oral RVV administration. However, the WASH intervention significantly increased RVV seroconversion by 50% (19.6% in non-WASH arm versus 30.3% in 93 94 the WASH arm) [20]. We hypothesised that the WASH intervention had reduced the burden of enteropathogens in these infants, thereby improving RVV immunogenicity. 95 However, the WASH intervention had no effect on enteropathogen carriage [21] and 96 97 enteropathogen burden was not associated with RVV immunogenicity [22]. In this follow-on study, we explore whether alterations in the composition of the gut 98 microbiome are associated with RVV immunogenicity, by conducting whole 99 metagenome shotgun sequencing of stool samples from infants around the time of 100 RVV. Here we report on (i) the composition and function of the early-life gut 101 microbiome in this rural LMIC setting and (ii) its association with RVV immunogenicity. 102

103

104

#### 105 MATERIALS AND METHODS

106

107 <u>Study population</u>

108 We present a sub-study of the Sanitation Hygiene Infant Nutrition Efficacy (SHINE) 109 trial [19], a 2×2 factorial cluster-randomized trial assessing the independent and 110 combined effects of improved WASH and improved infant and young child feeding

(IYCF) on stunting and anaemia (NCT01824940). Briefly, 5280 pregnant women in 111 112 rural Zimbabwe were enrolled and cluster-randomized to standard-of-care, IYCF, WASH or combined IYCF+WASH, and children were followed up until 18 months of 113 age. 1169 HIV-unexposed children were enrolled in a sub-study of the SHINE trial 114 which involved longitudinal specimen collection (including plasma and stool) at 1, 3, 115 116 6, 12 and 18 months of age [23]. Sterile collection tubes were provided to mothers, who collected stool samples from their infants on the day of the study visit. Blood 117 118 samples were collected from infants by trained nurses. Samples were transported by motorbike in cool boxes to field laboratories where they were aliquoted and stored at 119 -80°C before subsequent transport to the central laboratory in Harare for ongoing 120 121 storage. 158 infants with available plasma samples, oral rotavirus vaccine records and stool samples collected within 30 days of either vaccine dose were selected for 122 analysis in this study. The SHINE trial was approved by the Medical Research Council 123 of Zimbabwe and the Johns Hopkins Bloomberg School of Public Health Committee 124 on Human Research. Written informed consent was obtained from all caregivers 125 before enrolment in the trial. 126

127

#### 128 Sub-study population

For this study, infants were selected if they had at least one plasma sample collected post-rotavirus vaccination and an available stool sample collected at either 1 or 3months of age, as per previous analyses [22]. We permitted a 30-day window of stool collection pre- or post-vaccination (either RVV dose), hypothesizing that the gut microbiome soon before, during or after vaccination may contribute to RVV immunogenicity. In order to assess the effect of this chosen 30-day time-window

around vaccination, we conducted two sensitivity analyses: first, employing a 135 136 restricted time-window to include those collected prior to 43 days of age (median age of sample collection); and second, restricting to samples collected within 14-days pre 137 or post-RVV. Infants were excluded if they did not have vaccination data recorded or 138 had not received at least one dose of RVV. If more than one sample was available per 139 140 child, the stool sample collected closest to the first dose of RVV was chosen for analysis. 158 participants meeting these criteria were included in this study. 67 of 141 142 these participants had previously been selected and had metagenome sequencing data generated as part of a separate investigation into longitudinal infant microbiota 143 maturation from the same cohort [24]. The remaining 91 samples were selected at 144 145 random for the current study, whilst oversampling seroconverters to increase statistical power, and processed in an identical manner. 146

147

#### 148 Rotavirus vaccination and anti-rotavirus Immunoglobulin A assay

Oral monovalent RVV (Rotarix<sup>™</sup>; GSK Biologicals) was introduced as part of the 149 national vaccination programme in Zimbabwe in May 2014 and was administered to 150 infants at 6 and 10 weeks of age. National vaccination coverage in 2015-2016 was 151 87-91% [25]. Vaccination was undertaken at local clinics as part of routine national 152 153 vaccination programmes and was not overseen by the SHINE trial team. Vaccination dates were recorded by SHINE study staff by reviewing child health cards. Plasma 154 anti-rotavirus immunoglobulin A (IgA) was measured on stored plasma samples by 155 156 enzyme-linked immunosorbent assay (ELISA) using methods previously described [26]. The primary outcome was RVV seroconversion, defined as a post-vaccine 157 plasma concentration of anti–rotavirus  $IgA \ge 20 \text{ U/mL}$  in infants who were seronegative 158

(<20 U/mL) pre-vaccination [27]. Secondary outcomes included anti–rotavirus IgA titre</li>
 and RVV seropositivity, defined as a post-vaccine titre ≥20 U/mL, regardless of pre vaccine titre. We refer to these outcomes collectively as RVV immunogenicity.

162

#### 163 <u>Stool metagenome sequencing</u>

164 DNA was extracted from ~200mg stool using the Qiagen PowerSoil Kit with bead beating. DNA quality was confirmed by spectrophotometry (SimpliNano) and 165 166 quantified by fluorometry (Qubit). 1µg DNA was used as an input for sequencing library preparation following the Illumina TruSeg PCR-free library preparation protocol, using 167 custom end-repair, adenylation and ligation enzyme premixes. Constructed libraries 168 169 were assessed for quality of concentration (qPCR) and size (Tapestation 2200) prior to pooling. 48 barcoded samples were pooled in each sequencing run. Positive 170 controls (ZymoBIOMICS) and DNA-free negative controls were included through all 171 steps including DNA extraction and library preparation. One negative control was 172 included in each sequencing pool. Whole metagenome sequencing was performed 173 with 125-nucleotide paired-end reads using either the Illumina HiSeg 2500 or HiSegX 174 platforms at Canada's Michael Smith Genome Sciences Centre, Vancouver, Canada. 175

*KneadData* was used with default settings to remove short reads (<60bp),</p>
duplicate reads, human and other non-microbial reads and to trim off adapters. Filtered
sequencing reads were processed through the *MetaPhlan3* pipeline [28] with default
settings to generate compositional data. *HUMAnN3* was used with default settings
using the UniRef90 database to generate functional annotations (enzyme commission
(EC) annotations and pathways) [29]. Compositional and functional data were filtered
using a minimum threshold of >0.1% and >0.0001% relative abundance, respectively.

Taxa were included in the analyses if present at a minimum threshold of 5%prevalence within the entire dataset.

A median of  $8.1 \pm 3.0$  million quality filtered reads were produced per sample. Sixteen negative controls were also sequenced with mean 734 quality-filtered reads (range = 149 to 11,432, SD = 3462). Following filtering of annotatable reads, 139 species were included in the final analysis, of which 4 were classified as co-abundance gene groups metagenomic assemblies (CAGs) for which no culture-derived representative exists.

191

#### 192 Statistical Analyses

193 All data were analysed using R (v.4.0.2). Beta-diversity was estimated using the Bray-Curtis dissimilarity index. Alpha diversity was assessed using the Shannon index and 194 the number of observed species. Differential abundance analysis was performed by 195 Wilcoxon rank sum test and Analysis of Composition of Microbiomes (ANCOM) [30]. 196 Random Forest machine learning models were performed using the randomForest 197 package (SIAMCAT package [31]) in which five-fold cross-validation was performed 198 with 100 iterations. Microbiome regression analyses were performed using the 199 MaAsLin2 package. Seven covariates were chosen for adjustment in regression 200 201 models and included age at stool sample collection, birthweight, exclusive breastfeeding status (recorded at 3 months old), sex, WASH randomized trial arm, 202 delivery mode and length-for-age Z-score (LAZ) around time of vaccination. These 203 204 covariates were chosen based on biological plausibility and previous evidence of their independent influence on RVV immunogenicity in the same cohort [32]. Multiple 205

- 206 comparisons were tested using Benjamini-Hochberg false discovery rate (FDR; q-
- 207 value <0.05).
- 208
- 209
- 210 **RESULTS**
- 211
- 212 Study cohort

213 Among 5280 women enrolled in the SHINE trial, there were 3989 live-born, HIVunexposed infants. Of these, 882 children had RVV immunogenicity measured and 214 158 of these had stool samples collected within 30 days of either vaccine dose and 215 216 with valid metagenome sequencing data. **Table 1** outlines the primary characteristics of the 158 participants in this analysis. Of these 158 participants, 115 had 217 seroconversion data available as a primary outcome (n=81 non-seroconverters, n=34 218 seroconverters; Figure 1a), whilst secondary outcomes (seropositivity status and IgA 219 titres) were available for all 158 infants (n=113 seronegative, n=45 seropositive). 220

The median age at first dose of RVV was 44 days [interquartile range (IQR): 42-49]. The median age at stool sample collection was 43 days (IQR: 35-68; **Figure 1b**). To test for and account for age-associated changes in microbiota composition, analyses were also split by early ( $\leq$  42 days) and late (> 42 days) stool samples.

225

#### 226 Microbiome alpha and beta diversity associations with RVV immunogenicity

PERMANOVA analysis identified a small but significant difference in beta diversity as measured by Bray-Curtis distances by seroconversion status (P = 0.035;  $R^2$  = 0.014; **Fig. 2a**), however this was largely explained by data dispersion (homogeneity of

dispersion test; P = 0.035). When split by median age of sample collection (43 days), 230 there was a significant difference in Bray-Curtis distances between early and late 231 samples (P <0.001; R<sup>2</sup> = 0.025; Fig. 2b). Beta diversity analyses did not indicate a 232 significant difference between samples collected immediately prior to or after the first 233 dose of RVV in samples collected in the first 60 days of life (Fig. S1a), suggesting that 234 235 there was no significant difference of the vaccine itself on gut microbiome beta diversity. No significant difference was observed between infants randomized to 236 237 WASH or non-WASH trial arms (Fig. S1b).

In sensitivity analyses, when restricting to samples collected within 14 days of 238 either vaccine dose (n=62 non-seroconverters, n=28 seroconverters), there was a 239 240 significant difference in Bray-Curtis distances by seroconversion status (P = 0.011; R<sup>2</sup>) = 0.022; Fig. S1 c), which was partly explained by data dispersion (P = 0.03). 241 However, there was no significant difference in Bray-Curtis distances by 242 seroconversion status when restricted to early samples ( $\leq$  42 days; n=79 samples; P 243 = 0.061;  $R^2$  = 0.024). In analysis of secondary outcomes, beta diversity differed 244 significantly by seropositivity status (P = 0.008;  $R^2 = 0.012$ ; Fig. S1 d) in the total 245 dataset, which was not explained by dispersion (P = 0.067), but not when restricted to 246 samples collected before  $\leq$  42 days (P = 0.113; R<sup>2</sup> = 0.019). 247

Alpha diversity, as measured by the Shannon index and number of observed species, did not significantly differ by seroconversion (Wilcoxon test: P = 0.369 & P =0.260 respectively; **Fig. 3a**) and was not associated with anti-rotavirus IgA titre in simple linear regression (P = 0.306; **Fig. 3b**). As expected, there were significant differences in alpha diversity between early and late samples (P = 0.032).

In sensitivity analyses, alpha diversity also did not differ by seroconversion status or seropositivity status when restricted to early samples (P = 0.333 and P =0.260, respectively) or when restricted to stool samples collected within 14 days of either RVV dose (data not shown). There was also no significant difference in alpha diversity by seropositivity status (P = 0.18; **Fig. S2a-b**) or by randomized WASH arms (**Fig. S2c**).

259

260 Infant microbiome taxonomic composition and association with RVV immunogenicity At the phylum level, samples were dominated by Actinobacteria (Fig. 3c). 261 Bifidobacterium longum was the most abundant species in the entire dataset 262 263 comprising a median 23% relative abundance, ranging from 0% to 97% across all samples. Escherichia coli. Collinsella aerofaciens. В. bifidum Β. 264 and pseudocatenulanum were the next most highly abundant across all datasets. 265 Differential abundance analysis showed no significant differences in relative 266 abundances of any taxa by seroconversion status (Wilcoxon ranked sum test, q > 267 0.05; Fig. 3d). This negative result was confirmed by the more stringent ANCOM 268 model, which included covariate adjustment for age at stool sample collection, 269 birthweight, exclusive breastfeeding status, sex, trial arm, delivery mode and LAZ 270 271 around vaccination. Six species were significantly differentially abundant between early and late samples (Wilcoxon, q < 0.05: B. longum, Streptococcus mitis, 272 Bacteroides ovatus, Colinsella aerofaciens, Staphylococcus hominis, Streptococcus 273 274 pneumoniae; Fig. 4a and S2e) which was confirmed by ANCOM following covariate adjustment. In analysis of secondary outcomes, no taxa were significantly different by 275 seropositivity status (Fig. S2f). In sensitivity analyses, when restricted to early 276

samples or restricted to samples collected within 14 days of either vaccine dose, no
taxa were significantly differentially abundant when compared by seroconversion or
seropositivity statuses. *Collinsella aerofaciens* was the only species significantly
different in relative abundance between WASH and non-WASH infants in this subcohort (**Fig. S2f**).

282 Random Forest models were also applied to the datasets to test whether microbiome features could predict seroconversion and age. Early and late samples 283 were strongly classified by the Random Forest model (receiver operating curve area 284 under the curve (AUC) 0.758; Fig. 4b). Random Forest regression of age produced 285 moderately strong models (P = 0.001;  $R^2 = 0.152$ ; 14% explained variation). However, 286 287 random Forest poorly classified seroconversion status (AUC 0.589; Fig. 4c). In analysis of other secondary outcomes, random forest also poorly classified 288 seropositivity (AUC 0.564; Fig. S3a) and WASH trial arm (AUC 0.5; Fig. S3b). 289

Regression models were built (MaAsLin2) to identify associations between gut microbial taxa and age or vaccine titres. Following FDR correction and adjustment for covariates, *Bacteroides thetaiotaomicron* was the only species significantly associated with IgA titre (P = 0.008). This effect held in sensitivity analyses using samples collected within 14 days of either vaccine dose (P = 0.053) whilst also indicating that *Slackia isoflavoniconvertens* was also associated with IgA titre in the restricted sensitivity dataset (P = 0.049).

297

Infant microbiome functional composition and association with RVV immunogenicity
 Metagenomic data were also analysed to assess microbiome functional pathways
 associated with age and RVV responses. Wilcoxon tests identified no functional

pathway or EC that differed significantly by seroconversion status. Random Forest 301 models of microbiome functional pathways also poorly classified seroconversion 302 status. Two metagenomic pathways (PWY-5994: palmitate biosynthesis I (animals 303 and fungi and PWY-1042: glycolysis IV (plant cytosol)) and 153 ECs were 304 differentially abundant between early and late samples (Fig. 5). Random Forest 305 306 models performed moderately well in classifying early and late samples based on metagenomic pathways (AUC 0.641; Fig. S3c). No EC or metagenomic pathway was 307 308 significantly associated with IgA titre. In sensitivity analyses of early samples or those collected within 14 days of either vaccine dose, no EC or metagenomic pathway was 309 associated with seroconversion and random forest classification was poor. No 310 311 significant functional differences were observed by seropositivity status.

312

313

#### 314 **DISCUSSION**

Here, we report on the stool metagenomes of 158 infants <6 months of age from a 315 rural Zimbabwean birth cohort and their association with RVV immunogenicity. Similar 316 to other low-income settings, RVV was poorly immunogenic in this cohort (24% 317 seroconversion). The reasons for this are unclear, but dynamic changes in the 318 319 microbiota at this age may influence mucosal immune responses to an oral vaccine. However, we demonstrate here that there is no distinct gut microbiome signature that 320 distinguishes RVV seroconverters from non-seroconverters. Hence, poor vaccine 321 322 seroconversion in this population does not appear to be explained by the gut microbiome. 323

A handful of previous studies have demonstrated conflicting evidence for the 324 association between the infant gut microbiome and oral RVV efficacy. A previous 325 analysis of 170 infants in south India, using 16S amplicon sequencing, failed to find 326 an association between the commensal infant gut microbiome and RVV 327 seroconversion [16]. In the same study, however, RVV seroconverters were more 328 329 likely to harbour at least one bacterial enteropathogen than non-seroconverters. Conversely, two separate studies in Ghana (n=20) [18] and Pakistan (n=78) [17], 330 331 employing HITChip microarrays rather than next-generation sequencing, both demonstrated that the gut microbiome of RVV seroconverters differed significantly to 332 non-seroconverters. Both of these studies also reported that the gut microbiome of 333 334 seroconverters versus non-seroconverters were more similar to infants from a highincome setting in the Netherlands. However, the taxa associated with RVV 335 seroconversion differed between countries. Higher relative abundances of Clostridium 336 cluster XI and Proteobacteria were associated with seroconversion in Pakistan, whilst 337 higher Streptococcus bovis and lower Bacteroidetes were associated with 338 seroconversion in Ghana. 339

Due to the methodological differences in sequencing and the geographic 340 differences in the cohorts, it is difficult to draw comparisons with these previous 341 studies. Geographic setting has a major influence on gut microbiome composition and 342 inter-individual variation between children across geographical settings is greater than 343 in adults [33]. The results presented here, using gold-standard metagenome 344 345 sequencing, failed to find a clear infant microbiome signature that distinguished RVV seroconverters from non-seroconverters. Previous evidence shows that the strongest 346 contributor to infant gut microbiome composition in early-life is exclusivity of 347

breastfeeding [34], which was extremely high in this cohort (>80%) due to study interventions designed to promote early and exclusive breastfeeding. Hence, any gut microbiome signatures associated with RVV seroconversion may be outweighed by the influence of breastfeeding and other exposures on the early-life microbiome.

We recently reported that enteropathogen carriage was not associated with 352 353 RVV seroconversion in this cohort [22]. The results presented here extend these observations by showing that neither commensal nor pathogenic enteric microbes 354 355 influenced RVV seroconversion. Oral RVV is taken up in the small intestine, whereas the gut microbiome and enteropathogen carriage measured in stool largely reflect the 356 colonic intestinal environment. This may partly explain why we observed no 357 association between the stool microbiota and RVV seroconversion in this cohort. 358 Future studies examining the small intestinal microbiota may provide greater insight 359 into the potential interaction between the commensal gut microbiome and oral 360 vaccines. It remains unclear what biological factors contribute to poor RVV 361 immunogenicity in low-income settings. Improved WASH enhanced RVV 362 immunogenicity by 50% in this cohort [20], yet had no impact on enteropathogen 363 carriage [21] or diarrhea [19]. In this subset of infants, WASH similarly had no 364 significant impact on the early-life gut microbiome, suggesting that the effect of WASH 365 366 on RVV immunogenicity is not driven through the gut microbiome. Hence, the causal pathway linking improved WASH with improved RVV seroconversion remains 367 unexplained and complex. 368

This study benefited from a well-characterized cohort of infants from a large, community-based, cluster randomized trial. RVV seroconversion, measured in a subset of infants, was 23.7% rate despite high vaccine coverage, demonstrating its

suitability as a representative infant population with low RVV immunogenicity. Within 372 373 this subgroup, we have previously investigated and reported on a number of environmental factors associated with RVV seroconversion including enteropathogen 374 carriage, WASH, household factors, birthweight and nutritional status [20, 22, 32]. 375 Hence the data presented here, albeit negative, add to the evidence base of RVV 376 377 immunogenicity in a unique, well-characterised cohort by contributing unique insight into the intestinal milieu and its association with oral vaccine efficacy. We employed 378 379 whole metagenome shotgun sequencing, which has not previously been extensively conducted in low-income settings, allowing us to examine both taxonomic and 380 functional microbiome variables in relation to RVV seroconversion. It is also one of the 381 very few high-resolution, metagenomic datasets from infants in a rural, non-382 industrialized setting. 383

384 The study is limited by its relatively small sample size, which is partly due to the low seroconversion rate in this population, the number of stool samples available for 385 sequencing analysis and the criteria of sample selection within a 30-day time-window 386 close to vaccination. This arbitrary time-window was based on the hypothesis that the 387 intestinal environment around the time of vaccination may alter vaccine efficacy and 388 was chosen to complement our previous analyses in this same cohort using the same 389 cut-off around vaccination [22]. The study is limited by this chosen time-window which 390 may lead to confounding effects of age on any potential gut microbiome associations. 391 To mitigate this, we adjusted for age in all regression models and also performed 392 393 sensitivity analyses using a restricted 14-day time window and analysing a subset of 'early' samples collected before 43 days of age (median age of sample set). Secondly, 394 the outcomes assessed in this study (seroconversion and seropositivity) may not be 395

accurate correlates of vaccine protection. We focussed on seroconversion as a 396 397 primary outcome as this depends on both pre and post-vaccine titres and also included seropositivity as a secondary analysis. However, as we and others have reported [32], 398 natural rotavirus infection prior to vaccination may confound IgA titres which limits both 399 seroconversion and seropositivity in particular as an outcome. Furthermore, 400 401 seroconversion and seropositivity are not perfect correlates of protection against rotavirus protection [35]. Thirdly, due to the difficulties in obtaining viral reads from 402 403 stool metagenomic data, we were unable to determine the impact of enteroviruses on RVV seroconversion, which has been hypothesized previously to be associated with 404 RVV immunogenicity [16]. Specific analysis of the infant virome may shed more light 405 on RVV underperformance. 406

In conclusion, we found no clear stool microbiome signature associated with oral RVV immunogenicity in rural Zimbabwean infants. Further research into other intestinal and additional biological pathways that explain poor oral vaccine immunogenicity in low-resource settings is warranted.

411

#### 412 FUNDING

This work was supported by the Wellcome Trust [203905/Z/16/Z to JAC, 206455/Z/17/Z to RCR and 093768/Z/10/Z and 108065/Z/15/Z to AJP]. The SHINE trial was funded by the Bill and Melinda Gates Foundation [OPP1021542 and OPP113707]; UK Department for International Development (UK Aid); Swiss Agency for Development and Cooperation and US National Institutes of Health [2R01HD060338-06]. The study funders approved the trial design, but were not involved in data collection, analysis, interpretation, or manuscript preparation.

420

### 421 CONFLICT OF INTEREST

422 The authors declare no conflicts of interest

423

424

#### 425 ACKNOWLEDGEMENTS

The authors thank all the mothers, babies and their families who participated in THE 426 427 SHINE trial. The authors gratefully acknowledge the leadership and staff of the Ministry of Health and Child Care in Chirumanzu and Shurugwi districts and Midlands 428 Province (especially environmental health, nursing and nutrition) for their roles in 429 430 operationalization of the study procedures. The authors acknowledge the Ministry of Local Government officials in each district who supported and facilitated field 431 operations. The authors also acknowledge Monica M. McNeal for her invaluable 432 support in setting up the anti-rotavirus IgA assay. 433

434

435

436 All authors attest they meet the ICMJE criteria for authorship.

#### REFERENCES

- Collaborators GDD. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis **2018**; 18(11): 1211-28.
- 2. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis **2009**; 200 Suppl 1: S39-48.
- 3. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med **2006**; 354(1): 11-22.
- Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med **2006**; 354(1): 23-33.
- Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet **2010**; 376(9741): 615-23.
- Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet **2010**; 376(9741): 606-14.
- Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet **2013**; 382(9888): 209-22.
- Parker EP, Ramani S, Lopman BA, et al. Causes of impaired oral vaccine efficacy in developing countries. Future Microbiol **2018**; 13: 97-118.

- Church JA, Parker EP, Kirkpatrick BD, Grassly NC, Prendergast AJ. Interventions to improve oral vaccine performance: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19(2): 203-14.
- Robertson RC, Manges AR, Finlay BB, Prendergast AJ. The Human Microbiome and Child Growth - First 1000 Days and Beyond. Trends Microbiol **2019**; 27(2): 131-47.
- 11. Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J Infect Dis **2014**; 210(2): 171-82.
- 12. Shi Z, Zou J, Zhang Z, et al. Segmented Filamentous Bacteria Prevent and Cure Rotavirus Infection. Cell **2019**; 179(3): 644-58.e13.
- de Jong SE, Olin A, Pulendran B. The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host Microbe **2020**; 28(2): 169-79.
- 14. Lynn MA, Tumes DJ, Choo JM, et al. Early-Life Antibiotic-Driven Dysbiosis Leads to Dysregulated Vaccine Immune Responses in Mice. Cell Host Microbe **2018**; 23(5): 653-60.e5.
- Harris VC, Haak BW, Handley SA, et al. Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of-Concept Trial. Cell Host Microbe 2018; 24(2): 197-207.e4.
- Parker EPK, Praharaj I, Zekavati A, et al. Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine **2018**; 36(2): 264-72.
- 17. Harris V, Ali A, Fuentes S, et al. Rotavirus vaccine response correlates with the infant gut microbiota composition in Pakistan. Gut Microbes **2018**; 9(2): 93-101.

- Harris VC, Armah G, Fuentes S, et al. Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana. J Infect Dis **2017**; 215(1): 34-41.
- Humphrey JH, Mbuya MNN, Ntozini R, et al. Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. Lancet Glob Health **2019**; 7(1): e132e47.
- 20. Church JA, Rukobo S, Govha M, et al. The impact of improved water, sanitation and hygiene on oral rotavirus vaccine immunogenicity in Zimbabwean infants: sub-study of a cluster-randomized trial. Clin Infect Dis **2019**.
- Rogawski McQuade ET, Platts-Mills JA, Gratz J, et al. Impact of Water Quality, Sanitation, Handwashing, and Nutritional Interventions on Enteric Infections in Rural Zimbabwe: The Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial. J Infect Dis 2020; 221(8): 1379-86.
- 22. Church JA, Rogawski McQuade ET, Mutasa K, et al. Enteropathogens and Rotavirus Vaccine Immunogenicity in a Cluster Randomized Trial of Improved Water, Sanitation and Hygiene in Rural Zimbabwe. Pediatr Infect Dis J **2019**; 38(12): 1242-8.
- Prendergast AJ, Humphrey JH, Mutasa K, et al. Assessment of Environmental Enteric Dysfunction in the SHINE Trial: Methods and Challenges. Clin Infect Dis 2015; 61 Suppl 7: S726-32.
- 24. Gough EK, Prendergast AJ, Mutasa KE, Stoltzfus RJ, Manges AR, Team SHINEST. Assessing the Intestinal Microbiota in the SHINE Trial. Clin Infect Dis **2015**; 61 Suppl 7: S738-44.
- UNICEF. Zimbabwe: WHO and UNICEF estimates of immunization coverage: 2016 revision. .
   2016.

- 26. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine **1998**; 16(4): 381-7.
- 27. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis **1989**; 159(1): 79-88.
- Truong DT, Franzosa EA, Tickle TL, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods **2015**; 12(10): 902-3.
- 29. Franzosa EA, McIver LJ, Rahnavard G, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods **2018**; 15(11): 962-8.
- Mandal S, Van Treuren W, White RA, Eggesbø M, Knight R, Peddada SD. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis 2015; 26: 27663.
- 31. Wirbel J, Zych K, Essex M, et al. SIAMCAT: user-friendly and versatile machine learning workflows for statistically rigorous microbiome analyses. bioRxiv **2020**.
- 32. Church JA, Chasekwa B, Rukobo S, et al. Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean infants. Vaccine **2020**; 38(13): 2870-8.
- 33. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature **2012**; 486(7402): 222-7.
- 34. Stewart CJ, Ajami NJ, O'Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature **2018**; 562(7728): 583-8.
- 35. Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol **2015**; 8(1): 1-17.

#### FIGURE LEGENDS

**Fig 1. Study flow.** (a) Flow diagram of stool samples included in the analysis originating from the SHINE trial. (b) Timing of stool samples included in the analysis and associated RVV doses.

**Fig. 2. Beta diversity analysis by seroconversion status and early vs late samples.** Principal coordinates analysis (PCoA) and associated Bray-Curtis distances to assess beta diversity of seroconversion status (a) and early vs late samples (b) as assessed using PERMANOVA analysis.

**Fig. 3. Alpha diversity and taxonomic composition.** (a) Alpha diversity, as assessed using the Shannon index and number of observed species, between serconverters and non-seroconverters. (b) Associations between alpha diversity, age at stool sample collection and RV IgA titre. (c) Phylum composition of entire dataset. (d) Species composition in seroconverters vs non-seroconverters.

Fig. 4. Differential abundance analysis and machine learning models of taxonomic composition. (a) Species that differ significantly in relative abundance between early ( $\leq$  42 days) and late (> 42 days) samples as assessed by Wilcoxon ranked sum test (q value < 0.05). Random Forest machine learning classification model of (a) early vs late samples and (b) seroconverters vs non-seroconverters using all microbiome species.

**Fig. 5. Functional metagenomic analysis.** Enzyme commission annotations that differ significantly in relative abundance between early vs late samples (Wilcoxon rank sum test; q value < 0.05; top 20 ECs shows as ranked by q-value).

### Table 1.

	Seroconversion			Seropositivity		
	Non-seroconverters	Seroconverters	P value	Seronegative	Seropositive	P value
	N=81	N=34		N=113	N=45	
Female, %	61.7	55.9		59.3	48.9	
Birthweight, kg (sd)	3.17 (0.48)	3.06 (0.55)	0.303	3.11 (0.49)	3.06 (0.50)	0.564
Low birthweight, %	4.94	11.8		7.96	8.89	
Vaginal delivery, %	96.3	97.1		95.6	95.6	
Institutional delivery, %	91.2	94.1		93.8	95.6	
Exclusively breastfed (at month 3), %	90.0	97.1		90.1	95.5	
Concurrent OPV vaccination, %	95.7	93.8		96.5	92.1	
Age at stool sample, days [IQR]	38 [34; 66]	37 [33; 41]	0.222	45 [35; 78]	38 [34; 59]	0.034
Age at first RV dose, days [IQR]	46 [43; 54]	44 [42;45]	0.002	45 [42; 50]	44 [42; 45]	0.019
Age at second RV dose, days [IQR]	82 [74; 100]	77 [75;82]	0.037	78 [72; 93]	77 [75; 83]	0.669
LAZ at 1 month visit (sd)	-0.88 (1.09)	-0.80 (1.43)	0.783	-1.00 (1.19)	-0.73 (1.33)	0.267
LAZ at 3 month visit (sd)	-0.90 (1.07)	-0.84 (1.19)	0.786	-0.94 (1.13)	-0.88 (1.25)	0.791
WASH trial arm, %	42.0	47.1		41.6	51.1	
Born in RV season, %	33.3	44.1		29.2	37.8	
Household size	5 [4; 6]	5 [4; 6]	0.126	5 [4; 6]	5 [4; 6]	0.298
Mother age at baseline, years (sd)	27.9 (5.8)	27.3 (6.1)	0.659	27.6 (6.0)	27.2 (6.5)	0.787
Mother height at baseline, cm (sd)	160.7 (6.2)	160.7 (6.0)	0.983	160 (5.9)	161 (6.2)	0.722









### Significance





Abundance (log10-scale)

-log10(adj. p value)